San Francisco-based Katalyze AI has raised $10.5 million in seed funding to expand its agentic operating system designed to help pharmaceutical companies automate complex engineering, scientific, and manufacturing workflows.
The funding round was led by Bonfire Ventures, along with Inovia Capital, Ripple Ventures, Alumni Ventures, and leading angel investors including Gokul Rajaram and Farzad Soleimani.
Already deployed across five of the 20 largest global pharmaceutical companies, Katalyze says its platform has enabled pharma teams to deliver 10 million medication doses to patients with greater speed, reliability, and operational visibility.
The company’s platform allows scientists, engineers, and analysts at biopharma companies to build teams of AI agents that perform real engineering, scientific, and manufacturing work.
Addressing the Growing Complexity of Drug Development
The pharmaceutical industry faces increasing pressure to accelerate the path from drug discovery to patient delivery as companies deal with patent expirations and continued challenges around drug shortages.
Katalyze AI is building its platform around the belief that pharmaceutical AI applications require a higher level of accuracy than general-purpose AI tools. The company says its technology is designed for situations where approximate answers are not sufficient and results must be consistently accurate.
Building an Agentic Operating System for Pharma
Katalyze AI’s platform connects fragmented pharmaceutical data across plant and laboratory systems through MCP, a command-line interface, and integrations with existing enterprise systems including MES, LIMS, ELN, historians, and SAP.
The company says this creates a single source of truth where both people and AI agents can reason over data while maintaining verification, traceability, and compliance requirements.
The platform is designed to operate within GxP, data privacy, and data sovereignty requirements, allowing pharmaceutical companies to deploy AI agents in regulated environments. Katalyze says deployments can be completed in weeks, helping reduce timelines from idea to dose while lowering the cost of commercializing new medicines.
“What really separated Katalyze was that it was built for an enterprise like Sanofi from day one. The ontology layer was already in place. Data ingestion into the intelligence layer was solved. They had the security, the governance, the deployment story, everything we needed to scale this across R&D, not just run a pilot in one corner of the organization,” said Sabya Dasgupta, Global Head (VP) R&D Data Platforms & Products at Sanofi.
At the center of Katalyze’s platform is a dynamic context layer for every molecule, built around an operations-specific ontology and knowledge graph. This system grounds AI agents in real facility data, allowing outputs to be traced back to an immutable source.
The company also works with a community of more than 100 scientists and engineers from companies including Pfizer, Sanofi, and Eli Lilly and Company to develop specialized skills for its agents.
In one early deployment, Katalyze completed an analysis that would have previously taken one year and between $4 million and $6 million in costs in just 45 minutes.
Katalyze AI Platform Features
The company’s platform includes:
- Operational Data Layer: Unifies fragmented data across manufacturing plants and laboratories into a single, real-time operational source of truth, eliminating manual data assembly.
- Primary Production Record: Provides a GxP-native ontology layer using an operations-specific ontology and knowledge graph to connect every AI agent decision and insight back to its source.
- Katalyze Agent Catalog: Provides domain-trained agents designed for pharmaceutical workflows, including investigating deviations, tracking CAPAs, and drafting APQRs.
- Agent Studio: Allows internal scientists and data engineers to create custom proprietary agents on the same secure, source-grounded platform.
“The pressure to get medicine to patients faster, and at lower cost, has never been higher, but the bar for accuracy in our industry is absolute,” said Reza Farahani, Co-Founder and CEO of Katalyze AI. “We built an agentic operating system where every answer is grounded in an immutable record, so teams can deploy agents that are right every time and cut lab and manufacturing cycles from quarters to weeks, without ever exposing sensitive data.”
“Most AI in this category is a thin copilot bolted onto legacy tools,” said Brett Queener, General Partner at Bonfire Ventures. “Katalyze went the other way and built real infrastructure. By putting a GxP-native context layer underneath autonomous agents, they let AI reason across the messy, fragmented data of pharma manufacturing and actually do the work: solving deviations faster, improving yield, running critical workflows at a fraction of the cost. That’s the unlock the industry has been waiting for, and Reza’s team is the one delivering it.”
Expanding the Team and Scaling Deployments
Katalyze AI was founded by Reza Farahani (CEO), Shreyas Becker (COO), Hannes Bretschneider (Chief AI Officer), and Matt Cruz (Founding Engineer).
The founding team brings experience building startups across artificial intelligence, enterprise technology, and life sciences. The company has also assembled employees and advisors with backgrounds spanning Sanofi, OpenAI, Johnson & Johnson, and other leading life sciences and AI organizations.
With the new funding, Katalyze plans to expand its engineering, science, and go-to-market teams, grow its catalog of domain-trained AI agents, and scale deployments with major pharmaceutical companies.
Katalyze AI is headquartered in San Francisco. Its platform is currently used by five of the 20 largest global pharmaceutical companies.
